ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2

Overview

Journal Invest Ophthalmol Vis Sci

Specialty Ophthalmology

Date 2024 Jul 9

PMID 38980270

Authors

Robyn H Guymer

Rufino Silva

Mercedeh Ghadessi

Sergio Leal

Isabella Gashaw

Amy Damask

Charles Paulding

Kay D Rittenhouse

Affiliations

Soon will be listed here.

Abstract

Purpose: This analysis investigated potential associations between gene variants and clinical end points in the VIEW 1 and 2 randomized clinical trials of intravitreal aflibercept and ranibizumab in neovascular age-related macular degeneration (AMD).

Methods: A genome-wide association analysis was conducted in a subgroup of patients from VIEW 1 and 2 consenting to the optional pharmacogenetic analysis.

Results: Data were pooled from 780 samples from patients representative of the overall VIEW 1 and 2 populations. After Bonferroni correction for multiplicity and statistical adjustment for baseline risk factors, no significant associations were found between previously identified prognostic AMD gene variants and treatment response according to key prespecified VIEW 1 and 2 end points. Genome-wide, there were no significant genetic associations in patients experiencing gains of ≥15 Early Treatment of Diabetic Retinopathy Study letters after 1 or 2 years of treatment. A cluster of variants in ANO2 (encoding anoctamin 2, a calcium-activated chloride channel expressed on photoreceptor cells) on chromosome 12 reached the level of significance for loss of ≥5 letters after 1 year of treatment (P < 5 × 10-8), with the ANO2 rs2110166 SNP demonstrating highly significant association (P = 1.99 × 10-8). Carriers of the ANO2 rs2110166 TT genotype showed a robust increase in visual acuity versus baseline compared with a small decrease in those with the TC genotype.

Conclusions: None of the potential prognostic candidate genes were associated with the clinical end points for treated patients. Preliminary analyses suggest an association of ANO2 with retinal function, with a potential impact on vision of approximately one line over at least the first year. Further investigation of the function of ANO2 in retinal pathophysiology is merited.

References

Swaroop A, Chew E, Bowes Rickman C, Abecasis G . Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. Annu Rev Genomics Hum Genet. 2009; 10:19-43. PMC: 3469316. DOI: 10.1146/annurev.genom.9.081307.164350. View

Singh N, Swaroop A, Ratnapriya R . Making Biological Sense of Genetic Studies of Age-Related Macular Degeneration. Adv Exp Med Biol. 2021; 1256:201-219. DOI: 10.1007/978-3-030-66014-7_8. View

Seddon J, Ajani U, Mitchell B . Familial aggregation of age-related maculopathy. Am J Ophthalmol. 1997; 123(2):199-206. DOI: 10.1016/s0002-9394(14)71036-0. View

Finger R, Wickremasinghe S, Baird P, Guymer R . Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration. Surv Ophthalmol. 2013; 59(1):1-18. DOI: 10.1016/j.survophthal.2013.03.009. View

Ratnapriya R, Sosina O, Starostik M, Kwicklis M, Kapphahn R, Fritsche L . Retinal transcriptome and eQTL analyses identify genes associated with age-related macular degeneration. Nat Genet. 2019; 51(4):606-610. PMC: 6441365. DOI: 10.1038/s41588-019-0351-9. View

Wu M, Xiong H, Xu Y, Xiong X, Zou H, Zheng M . Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis. Br J Ophthalmol. 2017; 101(7):976-984. PMC: 5530807. DOI: 10.1136/bjophthalmol-2016-309418. View

Heier J, Khanani A, Quezada Ruiz C, Basu K, Ferrone P, Brittain C . Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022; 399(10326):729-740. DOI: 10.1016/S0140-6736(22)00010-1. View

Hong N, Shen Y, Yu C, Wang S, Tong J . Association of the polymorphism Y402H in the CFH gene with response to anti-VEGF treatment in age-related macular degeneration: a systematic review and meta-analysis. Acta Ophthalmol. 2016; 94(4):334-45. DOI: 10.1111/aos.13049. View

Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira M, Bender D . PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007; 81(3):559-75. PMC: 1950838. DOI: 10.1086/519795. View

10.

Burkholder B, Osborne B, Loguidice M, Bisker E, Frohman T, Conger A . Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. Arch Neurol. 2009; 66(11):1366-72. DOI: 10.1001/archneurol.2009.230. View

11.

Sorenson C, Gurel Z, Song Y, Peterson K, Blodi B, Sheibani N . Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients. PLoS One. 2024; 19(2):e0297135. PMC: 10896504. DOI: 10.1371/journal.pone.0297135. View

12.

Hagstrom S, Ying G, Maguire M, Martin D, Gibson J, Lotery A . VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration. Ophthalmology. 2015; 122(8):1563-8. PMC: 4516643. DOI: 10.1016/j.ophtha.2015.04.024. View

13.

Wang Z, Zou M, Chen A, Liu Z, Young C, Wang S . Genetic associations of anti-vascular endothelial growth factor therapy response in age-related macular degeneration: a systematic review and meta-analysis. Acta Ophthalmol. 2021; 100(3):e669-e680. DOI: 10.1111/aos.14970. View

14.

Kozhevnikova O, Fursova A, Derbeneva A, Nikulich I, Tarasov M, Devyatkin V . Association between Polymorphisms in CFH, ARMS2, CFI, and C3 Genes and Response to Anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration. Biomedicines. 2022; 10(7). PMC: 9312436. DOI: 10.3390/biomedicines10071658. View

15.

Schmidt-Erfurth U, Waldstein S . A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res. 2015; 50:1-24. DOI: 10.1016/j.preteyeres.2015.07.007. View

16.

Schreiber R, Kunzelmann K . Expression of anoctamins in retinal pigment epithelium (RPE). Pflugers Arch. 2016; 468(11-12):1921-1929. DOI: 10.1007/s00424-016-1898-2. View

17.

Schmidt-Erfurth U, Kaiser P, Korobelnik J, Brown D, Chong V, Nguyen Q . Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2013; 121(1):193-201. DOI: 10.1016/j.ophtha.2013.08.011. View

18.

Chen G, Tzekov R, Li W, Jiang F, Mao S, Tong Y . Pharmacogenetics of Complement Factor H Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis. Sci Rep. 2015; 5:14517. PMC: 4585967. DOI: 10.1038/srep14517. View

19.

Fritsche L, Igl W, Cooke Bailey J, Grassmann F, Sengupta S, Bragg-Gresham J . A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2015; 48(2):134-43. PMC: 4745342. DOI: 10.1038/ng.3448. View

20.

Csaky K, Richman E, Ferris 3rd F . Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci. 2008; 49(2):479-89. DOI: 10.1167/iovs.07-1132. View